The healthtech company secured ninety percent of the round from its own medical user base.
"This latest round represents a profound and unique endorsement of Pharmacierge by the very same Consultants and GPs who use it most often. They’ve recognised the huge value in our product, and have not only validated that as users, but also as investors."
Octopus Ventures led the financing round, which will fund technology development and team expansion.
"People who survive their cancers feel lost in transition. They can’t get the care they need, find the healthcare system confusing and uncoordinated, and continue to suffer with the late and long-term effects of curative cancer treatments. At Perci, with our growing team of specialists, we’re on a mission to change that."
The funding round will support the clinical development of the company's transdermal testosterone patch for post-menopausal women.
"Having the funding in place for the first clinical trial of our testosterone patch for post-menopausal women will enable Medherant to take a major step towards registration of the product and being able to address this significant gap in the options available for women in this very important stage of their lives."
The funding round was led by SFC Capital and OION to prepare the medical device startup for patient trials.
"A younger patient has about a 35% chance of implant failure during their lifetime, and the leading cause of failure is loss of fixation between the bone and the implant"